Mediators of Inflammation

Mediators of Inflammation / 1999 / Article

Open Access

Volume 8 |Article ID 395129 | https://doi.org/10.1080/09629359990667

I. Sermet-Gaudelus, V. Stoven, J. P. Annereau, V. Witko-Sarsat, P. Reinert, M. Guyot, B. Descamps-Latscha, J. Y. Lallemand, G. Lenoir, "Interest of Colchicine for the Treatment of Cystic Fibrosis Patients. Preliminary Report", Mediators of Inflammation, vol. 8, Article ID 395129, 3 pages, 1999. https://doi.org/10.1080/09629359990667

Interest of Colchicine for the Treatment of Cystic Fibrosis Patients. Preliminary Report

Abstract

Cystic fibrosis (CF) lung disease is characterized by persistent inflammation. Antiinflammatory drugs, such as corticosteroids and ibuprofene, have proved to slow the decline of pulmonary function although their use is limited because of frequent adverse events. We hypothesized that colchicine could be an alternative treatment because of its antiinflammatory properties and upregulatory effect on cystic fibrosis transmembrane regulator (CFTR) closely related proteins. We herein present results obtained in an open study of eight CF children treated with colchicine for at least 6 months. Clinical status was better in all patients and respiratory function tests significantly improved in five. Median duration of antibiotherapy decreased significantly. These preliminary results support our hypothesis of a beneficial effect of colchicine in CF patients and stress the need for a controlled therapeutic trial.

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views88
Downloads368
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.